Cargando…
Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In Silico
Amyloid-beta peptides have long been implicated in the pathology of Alzheimer’s disease. Bexarotene, a drug approved by the U.S. Food and Drug Administration for treating a class of non-Hodgkin’s lymphoma, has been reported to facilitate the removal of amyloid-beta. We have developed a mathematical...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830620/ https://www.ncbi.nlm.nih.gov/pubmed/27073866 http://dx.doi.org/10.1371/journal.pone.0153150 |